title: Various regimens for prophylactic treatment of patients with haemophilia.
abstract: Haemophilia prophylaxis is superior to on-demand treatment to prevent joint damage. 'High-dose prophylaxis' as used in Sweden is more effective in preventing arthropathy than an 'intermediate-dose regimen' (the Netherlands) and the Canadian tailored primary prophylaxis. Prophylaxis may reduce the risk of developing inhibitors. There is no difference in inhibitor risk between plasma derived and recombinant factor VIII (rFVIII) products but the Rodin study showed increased risk with second-generation rFVIII products. MRI is a new and very sensitive tool to detect the symptoms of early arthropathy but some results (soft tissue changes in 'bleed-free joints') still need to be investigated. Ultrasound is a very helpful method to aid diagnosis especially during the acute phase of a bleed. The risk of infection with central venous access remains a matter of debate. A fully implanted central venous access device (CVAD) has a significant lower risk of infection compared to external CVADs. Patient's age under 6 yr and inhibitor presence are additional risk factors for infections. The role of arteriovenous fistulae needs to be investigated because significant complications have been reported. Disease-specific quality of life instruments are complementary to generic instruments evaluating QoL in patients with haemophilia and have become important health outcome measures.
authors.affiliation: Childrens and Maternity Hospital, Linz, Austria.
authors.forename: Rudolf
authors.initials: R
authors.lastname: Schwarz
authors.forename: Rolf
authors.initials: R
authors.lastname: Ljung
authors.forename: Ulf
authors.initials: U
authors.lastname: Tedgård
mesh_terms: D000328:Adult; D000367:Age Factors; D000906:Antibodies / Q000097:blood*; D001168:Arthritis / Q000000981:diagnostic imaging / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D002405:Catheterization, Central Venous; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use*; D006395:Hemarthrosis / Q000000981:diagnostic imaging / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D006467:Hemophilia A / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007223:Infant; D007596:Joints / Q000098:blood supply / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008279:Magnetic Resonance Imaging; D011788:Quality of Life; D012307:Risk Factors; D014463:Ultrasonography
chemical_list: D000906:Antibodies; D005169:Factor VIII
keywords: children; haemophilia; inhibitors; prophylaxis; treatment